On December 14, 2020 Modulus Discovery Inc. ("Modulus"), a pre-clinical stage technology-driven drug discovery company reported that it was invited to present at the 39th Annual J.P. Morgan Healthcare Conference in January 2021 (Press release, Modulus Discovery, DEC 14, 2020, View Source [SID1234574447]). The J.P. Morgan Healthcare Conference, which attracts over 500 companies and 12,000 investors, is going virtual for 2021, and the webcast will be made available online following the live event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

S. Roy Kimura, co-founder and CEO, will present on January 12, 2021 at 8:40 AM EST and will give a brief introduction to the company’s cutting edge simulation-based drug discovery platform and its maturing portfolio of small-molecule drug discovery projects in chronic inflammation, oncology, and infectious diseases including COVID and related RNA viruses. Following the event, the company will be available for meetings with interested parties to further describe its unique discovery platform and capabilities and lead programs currently in pre-clinical studies.

Comment from S. Roy Kimura, CEO, Modulus Discovery, Inc.
"We are delighted to be given this opportunity to introduce our company’s technology platform, small-molecule discovery capabilities, and unique portfolio of R&D programs. Our lead programs targeting chronic inflammation / autoimmune diseases and oncology are currently approaching the IND stage, and we would be happy to provide information about them to interested parties for potential clinical partnerships."